Compare Recursion Pharmaceuticals Inc (RXRX) vs ZIM Integrated Shipping Services Ltd (ZIM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ZIM Integrated Shipping Services Ltd — how do they compare? Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B), while ZIM Integrated Shipping Services Ltd trades at $29.26 (market cap $3.63B). The key difference: ZIM Integrated Shipping Services Ltd is the larger of the two by market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | ZIM | |
|---|---|---|
Market Cap | $1.86B | $3.63B |
Sector | Health | Industrials |
52-Week High | $6.79 | $30.08 |
52-Week Low | $2.84 | $12.44 |
Enterprise Value | $1.38B | $7.30B |
Dividend Yield | — | 20.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
ZIM Integrated Shipping Services trades at $30.08, up 5.25% with a bullish technical signal from moving averages. The company shows mixed fundamentals with Q2 2026 earnings beating expectations but declining profitability margins year-over-year. Valuation metrics appear attractive with P/S of 0.56 and P/B of 0.93, though analyst sentiment remains divided amid merger uncertainty with Hapag-Lloyd.
The stock faces headwinds from the uncertain $4.2 billion takeover deal and declining net income margins, but strong transpacific positioning and recent earnings beats provide upside potential. Current price sits well above the $18.25 consensus target, suggesting limited near-term upside according to Wall Street analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ZIM Integrated Shipping Services Ltd
ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →
